Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Vunakizumab (SHR-1314) in Healthy Subjects
NCT02934412Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Aug 2016
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vunakizumab in plaque psoriasis (6 arms), sponsored by Atridia Pty Ltd. Primary endpoint: Incidence and severity of adverse events at 70 days. Started Aug 2016; status: completed.
02
Drugs
vunakizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02934412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02934412.